The safety and tolerability of botulinum toxins for the treatment of cervical dystonia

Research output: Contribution to journalReview article

9 Scopus citations

Abstract

The use of botulinum toxin to treat cervical dystonia (CD) has dramatically improved the quality of life of patients with this disabling, often painful disease. Two forms of type A toxin (BOTOX® and Dysport®) and one form of type B toxin (MyoBloc®) are available in some parts of the world to treat patients with CD. The literature supports the efficacy of each in reducing the pain and movement of cervical dystonia. The dosing and side effects vary between the toxins. The potential availability of several forms of toxin will allow physicians to offer further treatment options to patients with CD. However, it is incumbent on the treating physicians to have a working knowledge of the different serotypes, different doses used of each formulation of each serotype, the side effect profile of each product and the potential for antibody formation for each form of toxin.

Original languageEnglish (US)
Pages (from-to)241-249
Number of pages9
JournalExpert Opinion on Drug Safety
Volume4
Issue number2
DOIs
StatePublished - Mar 1 2005
Externally publishedYes

    Fingerprint

Keywords

  • Botulinum toxins
  • Cervical dystonia
  • Clinical trials

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this